Table 4.
Combined characteristics of ITP cases vascularized with different modalities.
| Characteristics | PCI, n (%) (n = 18) | CABG, n (%) (n = 12) | Conservative, n (%) (n = 2) |
|---|---|---|---|
| Age (years) | 61 ± 15 | 60 ± 10 | 71 ± 6 |
| Male gender | 12 (67) | 9 (75) | 1 (50) |
| CAD | |||
| STEMI | 7 (39) | 2 (17) | 0 |
| NSTEMI | 5 (28) | 2 (17) | 2 (100) |
| UA | 6 (33) | 6 (50) | 0 |
| Stable CAD | 0 | 2 (17) | 0 |
| Baseline PLT (×109/L) | |||
| Mean ± SD | 58 ± 75 | 51 ± 28 | 7.5 ± 3.5 |
| Minimum | 2 | 8 | 5 |
| Maximum | 322 | 100 | 10 |
| ITP Treatment * | |||
| Steroids | 7 (39) | 1 (8) | 0 |
| IVIG | 3 (17) | 4 (33) | 0 |
| Steroids and IVIG | 5 (28) | 4 (33) | 1 (50) |
| None | 3 (17) | 1 (8) | 1 (50) |
| Antithrombotic therapy | |||
| DAPT < 12 months | 5 (28) | 0 | 0 |
| DAPT with unspecified duration | 9 (50) | 0 | 0 |
| Aspirin alone | 1 (6) | 1 (8) | 0 |
| None | 3 (17) | 0 | 2 (100) |
| No information | 0 | 11 (92) | 0 |
| Complications | |||
| Bleeding events | 2 (11) | 1 (8) | 0 |
| Death | 1 | 1 (8) | 0 |
| MI due to ITP treatment | 2 (11) | 1 (8) | 1 (50) |
*Two patients who underwent CABG received only PLT transfusion for ITP.
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease; STEMI, ST-elevation myocardial infarction; NSTEMI, non ST-elevation myocardial infarction; UA, unstable angina; PLT, platelet; IVIG, intravenous immunoglobulins; MI, myocardial infarction; ITP, immune thrombocytopenia purpura.